AI Drug Discovery Is Outgrowing Old Rules, and Regulators Are Running Behind
A new viewpoint argues that AI-powered drug discovery does not fit neatly into existing regulatory frameworks built around molecules, trials, and manufacturing rather than adaptive computational systems. The piece highlights a widening policy gap as AI moves from a research aid to a decision-making layer that can shape target selection, compound design, and development strategy.
AI in drug discovery is advancing faster than the rules designed to oversee it. The central issue is not whether regulators can evaluate drugs produced with computational tools; they already do that indirectly through established safety and efficacy standards. The harder question is how to govern systems whose outputs are influenced by opaque training data, evolving models, and iterative workflows that may materially shape what gets tested in humans.
That matters because AI is no longer confined to back-office hypothesis generation. In many discovery programs, models now influence target prioritization, molecular design, toxicity prediction, biomarker strategy, and even portfolio selection. When software helps determine which biological questions get pursued in the first place, the regulatory conversation shifts from validating a final asset to understanding the chain of machine-assisted decisions behind it.
A new regulatory approach would likely need to focus less on the simplistic idea of approving an algorithm and more on documenting provenance, validation boundaries, data lineage, and reproducibility. In practice, that could resemble a quality-system mindset for AI-enabled R&D: what data were used, how performance was tested, where the model is known to fail, and how human scientists intervened. Those disclosures may become especially important as companies market AI-generated pipelines to investors and partners.
The significance for healthcare AI is broader than drug discovery alone. This debate mirrors the shift already underway in clinical AI, where oversight is moving from abstract ethics principles toward operational governance. Drug regulators, biotech companies, and pharma partners are now confronting the same reality: once AI becomes part of the development substrate, policy can no longer treat it as a mere productivity tool.